Tannas Jatene

Leaflet Thrombosis in Surgically Explanted or Post-Mortem TAVR Valves

Leaflet thrombosis is currently one of the greatest concerns related to transcatheter aortic valve replacement (TAVR). Symptomatic valve thrombosis is a rare occurrence, but reduced leaflet motion, diagnosed by computed tomography, seems to be a more common finding [(1)][1]. We screened our

Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial

Cangrelor, a potent intravenous, reversible, platelet P2Y12 inhibitor, was recently approved by both the U.S. Food and Drug Administration and the European Medicines Agency as an adjunct for percutaneous coronary intervention. The approval was based on CHAMPION PHOENIX (A Clinical Trial Comparing

Prognostic value of renal function in patients with aortic stenosis treated with transcatheter aortic valve replacement

The objectives of the present study were to analyze the variation of renal function after transcatheter aortic valve replacement (TAVR) focused on acute kidney injury (AKI) and its impact on short‐ and mid‐term mortality.

Prospective comparison between three TAVR devices: ACURATE neo vs. CoreValve vs. SAPIEN XT. A single heart team experience in patients with severe aortic stenosis.

We sought to compare the new transcatheter aortic valve replacement (TAVR) device ACURATE neo (ACT) with the already established CoreValve (MCV) and SAPIEN XT (SXT) for the treatment of severe aortic stenosis (AS).

TAVR in patients with severe aortic stenosis and less than high risk: Future or present reality?

TAVR use is growing in patients with less than high surgical risk. Several registries, including this one, show excellent safety with TAVR in intermediate‐risk patients compared with similar patients undergoing SAVR. Long‐term data from ongoing randomized trials will answer definitively if we should routinely perform TAVR in intermediate‐risk patients.Key points TAVR use is growing in patients with less than high surgical risk. Several registries, including this one, show excellent safety with TAVR in intermediate-risk patients compared with similar patients undergoing SAVR. Long-term data from ongoing randomized trials will answer definitively if we should routinely perform TAVR in intermediate-risk patients.

Electrocardiography scar quantification correlates with scar size of hypertrophic cardiomyopathy seen by multidetector computed tomography

Hypertrophic cardiomyopathy (HCM), a genetically transmitted disease, is the most common genetic cardiovascular disease. Current strategies to stratify risk are expensive and concentrated in wealthy centers. Twelve‐lead electrocardiography (ECG) is inexpensive, universally available, and can be readily used for Selvester QRS scoring, which estimates scar size. This study aimed to establish the relation between ECG scar quantification and myocardial fibrosis (extent of myocardial delayed enhancement) in multidetector computed tomography (MDCT).

Second generation drug‐eluting stents versus bare‐metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET‐PROVE I and II trials

To compare mid‐term outcomes between patients undergoing proximal left anterior descending artery (LAD) percutaneous coronary intervention (PCI) with second generation drug‐eluting stent (DES) or bare‐metal stent (BMS).

TCT-312 Increased Cardiac Death and Stent Thrombosis in Chronic Obstructive Pulmonary Disease Patients Undergoing Percutaneous Coronary Intervention. An analysis of the BASKET-PROVE I and II trials

nos: 312 357 TCT-312 Increased Cardiac Death and Stent Thrombosis in Chronic Obstructive Pulmonary Disease Patients Undergoing Percutaneous Coronary Intervention. An analysis of the BASKET-PROVE I and II trials Tannas Jatene, Tor Biering-Sørensen, Kotaro Nochioka, Fernanda Mangione, Kim Hansen, Rikke Sørensen, Jan Skov Jensen, Peter Jørgensen, Raban Jeger, Christoph Kaiser, Matthias Pfisterer, Soeren Galatius Brigham and Women’s Hospital, Boston, Massachusetts, United States; Department of Cardiology, 2nd Medical School, Charles University and Motol University Hospital, Prague, Czech Republic; University of Texas Health Science Center at San Antonio; Beneficência Portuguesa de São Paulo Hospital, Boston, Massachusetts, United States; Department of Cardiology, 2nd Medical School, Charles University and Motol University Hospital, Prague, Czech Republic; Herlev & Gentofte Hospital, University of Copenhagen, Denmark; Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark; Emory University School of Medicine; Emory University School of Medicine; University Hospital Basel, Basel, Switzerland; University Hospital, Basel, Switzerland; Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark BACKGROUND COPD is associated with long-term all-cause death following PCI with bare-metal stents (BMS). Regarding other outcomes previous studies have shown conflicting results and the impact of drug-eluting stent (DES) in this population is not well known. We sought to evaluate the impact of chronic obstructive pulmonary disease (COPD) on percutaneous coronary intervention (PCI) outcomes, and the interaction with stent type. METHODS We analyzed 4605 patients that underwent PCI with BMS (33.1%) or DES (66.9%) from the BASKET-PROVE trials I and II. RESULTS COPD patients (n1⁄4283, 6.1%), were older and had more frequently a smoking or cardiovascular event history. At 2-year follow-up, cumulative event rates for patients with versus without COPD were the following: major adverse cardiac events [MACE: composite of cardiac death, non-fatal myocardial infarction (MI) and target vessel revascularization]: 15.2 vs. 8.1% (p<0.001); all-cause death: 11.7 vs. 2.4%, (p<0.001); cardiac death: 5.7 vs. 1.2%, (p<0.001); MI: 3.5 vs. 1.9% (p1⁄40.045); definite/probable/possible stent thrombosis: 2.5 vs. 0.9% (p1⁄40.01); and major bleeding: 4.2 vs. 2.1% (p1⁄40.014). After adjusting for confounders including smoking status, COPD remained an independent predictor for MACE (HR 1.80, 95%CI 1.31-2.49), all-cause death (HR 3.62, 95%CI 2.41-5.45), cardiac death (HR 3.12, 95%CI 1.74-5.60) and stent thrombosis (HR 2.39, 95% CI 1.035.54). We did not find evidence of an interaction between COPD and DES implantation (P for interaction 1⁄4 0.29). Model 1 Model 2

TCT-655 High Prevalence of TAVR Leaflet Thrombosis in a Single Center Pathological Review

TAVR is now widely used for the treatment of patients with severe aortic stenosis and high surgical risk, and recently has been shown to be a reasonable alternative among intermediate risk patients. Hemodynamic deterioration and thrombotic complications might be possible limitations to the expansion

TCT-381 Effects Of Acute Kidney Injury and Chronic Kidney Disease on Mortality In Patients Undergoing Transcatheter Aortic Valve Replacement.

Acute kidney injury (AKI) in patients with or without pre-existing chronic kidney disease (CKD) is strongly linked to decreased survival in patients treated with cardiac surgery but this is still incompletely understood after transcatheter aortic valve replacement (TAVR). This study sought to assess